Corbus Pharmaceuticals Holdings Culture | Comparably

Corbus Pharmaceuticals Holdings Unternehmenskultur

Corbus Pharmaceuticals Holdings Culture

Diese Punktzahl ergibt sich aus den Bewertungen und Beurteilungen der Mitarbeiter

Höchstbewertete Kulturdimensionen

N/A

Corbus Pharmaceuticals Holdings CEO

Yuval Cohen Corbus Pharmaceuticals Holdings' CEO
Yuval Cohen

Führungspositionen

Name & Titel
Biographie
Yuval Cohen  CEO / President
Yuval Cohen
CEO / President
Yuval Cohen serves as the CEO / President of Corbus Pharmaceuticals Holdings.
Scott Constantine M.S.  Director of Clinical Research & Operations
Scott Constantine M.S.
Director of Clinical Research & Operations
Scott Constantine, M.S. serves as Director of Clinical Research & Operations at Corbus Pharmaceuticals Holdings, Inc. Scott Constantine served as Director, Clinical Research & Operations at Insmed and Clinical, and Program Scientist at PTC Therapeutics with expertise in CF and pulmonary diseases.
Barbara White M.D.  Chief Medical Officer
Barbara White M.D.
Chief Medical Officer
Dr. Barbara White, M.D., has been the Chief Medical Officer at Corbus Pharmaceuticals Holdings, Inc. since August 2014. Dr. White served as Senior Vice President and Head of Research and Development of Stiefel Laboratories, Inc. since June 2011. Dr. White joined Stiefel in June 2011 and provides overall worldwide leadership to Stiefel's R&D function, with responsibility for all research and product development activities at Stiefel, including prescription and consumer products. She served as Vice President and Head of Immunology Therapeutic Area at UCB. Dr. White served as Vice President of Clinical Development, Inflammatory Disease of MedImmune, LLC since April 2, 2007. Dr. White joined MedImmune, LLC in January 2006 as Senior Director and served as Head of the Inflammatory Disease Group in Clinical Development since November 2006. Dr. White served as Director of Medical Affairs, Inflammation Therapeutic Area, at Amgen, where her activities included leading non-registration internal and external clinical research programs. Dr. White served as Professor of Medicine in the division of rheumatology and Vice Chairman of research, department of medicine at the University of Maryland School of Medicine. She served as an Associate Chief of staff of the research service at the Baltimore Veteran Administration (VA) Medical Center, one of the largest VA-based research programs in the country, where her research focused on immune-mediated mechanisms of lung fibrosis in scleroderma. Dr. White served as Co-Director of the Johns Hopkins University and University of Maryland Scleroderma Center. She has been active in the American College of Rheumatology, where she serves as a Director and an Ad Hoc Member of the FDA Arthritis Advisory Committee. She has served on the Editorial Boards of Arthritis & Rheumatism and Arthritis Care and Research and has been a reviewer for numerous journals and grant review panels. Dr. White has Medical Degree from the University of Pennsylvania School of Medicine and is Board Certified in Internal Medicine, Rheumatology and Allergy/Clinical Immunology. She completed her Postdoctoral Studies in basic Cellular Immunology at the National Institutes of Health.
Sean F. Moran CPA, MBA  Chief Financial Officer
Sean F. Moran CPA, MBA
Chief Financial Officer
Mr. Sean F. Moran, CPA, MBA, has been the Chief Financial Officer of Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Mr. Moran serves as the Chief Financial Officer at Corbus Pharmaceuticals, Inc. He served as an Acting Chief Financial Officer of InVivo Therapeutics Holdings Corp. from August 2013 to September 9, 2013. He served as the Chief Financial Officer at InVivo Therapeutics Holdings Corp. (Alternative Name: InVivo Therapeutics Corporation) since September 2010. He served as the Chief Financial Officer and Senior Vice President of Celsion Corp. from December 8, 2008 to January 8, 2010 and served as its Secretary until January 8, 2010. He served as the Chief Financial Officer and Vice President of Finance & Administration of Transport Pharmaceuticals Inc., from June 29, 2006 to 2008. He was Co-Founder of Anika Therapeutics Inc. and served as its Chief Financial Officer. He served as the Chief Financial Officer of Echo Therapeutics, Inc. (formerly Sontra Medical Corporation) from June 2002 to June 23, 2006 and also served as its Principal Accounting Officer and Secretary. He has over twenty-six years of experience in corporate financial management, mergers and acquisitions, investor and Wall Street relations and SEC reporting. He has a deep background in life sciences and has served in senior financial roles for medical device, biotech and drug development companies. He served as the Chief Financial Officer for public and private companies for sixteen years. He served as the Chief Financial Officer of SatCon Technology Corporation from 2000 to 2002. Prior to his employment with SatCon, he served as the Chief Financial Officer of Anika Therapeutics, Inc., from 1993 to 2000. He is a Certified Public Accountant. Mr. Moran holds a B.S. in Business Administration in 1980 and an M.B.A. in 1990 from Babson College.

Lassen Sie Corbus Pharmaceuticals Holdings wissen, dass Sie dort arbeiten möchten

Sagen Sie Corbus Pharmaceuticals Holdings, dass Sie interessiert sind dort zu arbeiten, ihre persönlichen Informationen bleiben dabei anonym. Comparably gibt Corbus Pharmaceuticals Holdings die Gelegenheit, Sie anzustellen. Wenn es eine passende Stelle gibt, matchen wir diese.

Corbus Pharmaceuticals Holdings H1B Visum

In 2019, hat sich Corbus Pharmaceuticals Holdings für 1 H1B Visa beworben. Von den beantragten Arbeitserlaubnissen wurden 100% genehmigt.

Arbeitserlaubnis Antrag Ergebnis

1
Insgesamt beantragt
  • 100% Gewährt (1 von 1)
  • 0% Verweigert ( von 1)
  • 0% Zurückgezogen Der Antrag wurde vom Arbeitgeber vor der Genehmigung / Ablehnung zurückgezogen ( von 1)
  • 0% Zertifiziert Zurückgezogen Der Antrag wurde genehmigt, aber später vom Arbeitgeber zurückgezogen ( von 1)

Diese Daten wurden unter Verwendung öffentlich bezogener Daten aus OFLC-Leistungsdaten< berechnet

Gleichberechtigungs Bewertung Wie positiv bewerten Frauen ihre Gesamterfahrung mit Corbus Pharmaceuticals Holdings

N/A

Herkunftsvielfalts Bewertung Wie positiv bewerten Minderheiten ihre Gesamterfahrung mit Corbus Pharmaceuticals Holdings

N/A

Kennen Sie jemanden, der bei Corbus Pharmaceuticals Holdings arbeitet?

Senden Sie ihnen eine Einladung, um die Unternehmenskultur zu bewerten.

Anonym Einladung versenden

×
Bewerten Sie Ihr Unternehmen